Lessons from measles vaccination in developing countries.

摘要: Difficulties in reaching and sustaining high enough coverage combined with the need to delay vaccination until most infants have lost maternal antibodies make it hard control measles standard titres of vaccine. Maternal are no longer a factor after 9 months developing countries 15 developed countries. It would be good vaccine which is effective younger order protect them before they exposed natural infection. Attendance at sessions also tends fall as children grow older. Since Edmonston-Zagreb proved immunogenic concentration ages 4-6 several World Health Organization 1989 recommended using where age major cause death. A shortage high-titre vaccines however led delays implementing this recommendation. The recommendation was subsequently rescinded data from 3 background infant mortality revealed increased overall among receiving compared recipients titre 9-10 months. This effect probably not been detected had trials carried out long-term an end point. These findings realerted scientific community funding agencies sparked development implementation new technological approaches develop may first few life prompted public health authorities adopt strategies. For now early schedules 2 doses given 1st year country populations risk morbidity age. Even though recent analysis by Aaby et al. found that declines unexpectedly relative efficacy safety double-dose approach has yet formally tested. finding excess focused attention on immune function vaccines. suspected disruption including imbalance type helper T cell response. suggest standard-titre reduce general immunostimulation. authors conclude urging vaccinations introduced only rigorous conducted